Abstract
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) catalyzes the interconversion of inactive cortisone to active cortisol in a NADPH dependent manner. Excess cortisol or 11β-HSD1 leads to insulin resistance and metabolic syndrome. Inhibition of 11β-HSD1 activity has been pursued vigorously by the pharmaceutical industry as a potential therapeutic strategy for the treatment of type 2 diabetes. As a result, a large number of chemical classes have been identified as potent and selective small molecule inhibitors for 11β-HSD1. Here we review the recent progress in the discovery and development of small molecule inhibitors of 11β-HSD1 by highlighting the medicinal chemistry, SAR, in vivo pharmacodynamic effects and efficacy of a few representative classes of inhibitors in models of diabetes. Furthermore, we also review the structural characteristics of each class of inhibitors by analyzing the inhibitor co-crystal structures of 11β- HSD1.
Keywords: 11β-HSD1, 11β-HSD2, metabolic syndrome, type 2 diabetes, sulfonamide, amide, triazole, insulin resistance, SAR, pharmacodynamic effects, efficacy, co-crystal structures, Glucocorticoids, anti-inflammatory hormones
Current Topics in Medicinal Chemistry
Title: Small Molecule 11β- Hydroxysteroid Dehydrogenase Type 1 Inhibitors
Volume: 11 Issue: 12
Author(s): Daqing Sun, Minghan Wang and Zhulun Wang
Affiliation:
Keywords: 11β-HSD1, 11β-HSD2, metabolic syndrome, type 2 diabetes, sulfonamide, amide, triazole, insulin resistance, SAR, pharmacodynamic effects, efficacy, co-crystal structures, Glucocorticoids, anti-inflammatory hormones
Abstract: 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) catalyzes the interconversion of inactive cortisone to active cortisol in a NADPH dependent manner. Excess cortisol or 11β-HSD1 leads to insulin resistance and metabolic syndrome. Inhibition of 11β-HSD1 activity has been pursued vigorously by the pharmaceutical industry as a potential therapeutic strategy for the treatment of type 2 diabetes. As a result, a large number of chemical classes have been identified as potent and selective small molecule inhibitors for 11β-HSD1. Here we review the recent progress in the discovery and development of small molecule inhibitors of 11β-HSD1 by highlighting the medicinal chemistry, SAR, in vivo pharmacodynamic effects and efficacy of a few representative classes of inhibitors in models of diabetes. Furthermore, we also review the structural characteristics of each class of inhibitors by analyzing the inhibitor co-crystal structures of 11β- HSD1.
Export Options
About this article
Cite this article as:
Sun Daqing, Wang Minghan and Wang Zhulun, Small Molecule 11β- Hydroxysteroid Dehydrogenase Type 1 Inhibitors, Current Topics in Medicinal Chemistry 2011; 11 (12) . https://dx.doi.org/10.2174/156802611795860988
DOI https://dx.doi.org/10.2174/156802611795860988 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biochemical Markers of Renal Function
Current Medicinal Chemistry Targeting Farnesoid-X-Receptor: From Medicinal Chemistry to Disease Treatment
Current Medicinal Chemistry DNA Methyltransferase-1 Inhibitors as Epigenetic Therapy for Cancer
Current Cancer Drug Targets Seasonal and Perennial Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery Lipid-Activated Nuclear Receptors and Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Joint Occurrence of Pain and Sleep Disturbances in People with Dementia. A Systematic Review
Current Alzheimer Research Viral Reservoirs an Impediment to HAART: New Strategies to Eliminate HIV-1
Current Drug Targets - Infectious Disorders Genome-wide Analysis of Myelodysplastic Syndromes
Current Pharmaceutical Design Mechanisms of Neuronal Injury and Death in HIV-1 Associated Dementia
Current HIV Research Therapeutic Potential for Thyroid Hormone Receptor-β Selective Agonists for Treating Obesity, Hyperlipidemia and Diabetes
Current Vascular Pharmacology Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology Newborn Screening through TREC, TREC/KREC System for Primary Immunodeficiency with limitation of TREC/KREC. Comprehensive Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Phosphotyrosine Phosphatases in Cancer Diagnostic and Treatment
Recent Patents on DNA & Gene Sequences Genetics of Bladder Malignant Tumors in Childhood
Current Genomics Epigenetics, Depression and Antidepressant Treatment
Current Pharmaceutical Design Effects of Diet-Derived Molecules on the Tumor Microenvironment
Current Angiogenesis (Discontinued) Breast Cancer: Current Developments in Molecular Approaches to Diagnosis and Treatment
Recent Patents on Anti-Cancer Drug Discovery Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets The Heat Stress Response and Diabetes: More Room for Mitochondrial Implication
Current Pharmaceutical Design Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Incorporating Fatty Acid-Modified Polyethylenimine
Current Pharmaceutical Biotechnology